Prescription Access resources. NeedyMeds. RxAssist.org. Together RX Access TogetherRxAccess.com
|
|
- Elaine Matthews
- 7 years ago
- Views:
Transcription
1 Prescription Access resources NeedyMeds RxAssist.org Together RX Access TogetherRxAccess.com The Partnership for Prescription Access 888-4PPA-NOW ( ) By Company: ABBOTT Abbott Patient Assistance Foundation (Lupron) Abbott Patient Assistance Foundation Abbott Patient Assistance Foundation - Diabetes Care Abbott Patient Assistance Foundation - Kaletra & Norvir Abbott Patient Assistance Foundation - Medical Nutrition Abbott Patient Assistance Foundation (HUMIRA) Abbott Patient Assistance Foundation (Zemplar)
2 ABRAXIS ONCOLOGY Abraxis Patient Access Program , opt 3 ACCREDO THERAPEUTICS Adagen Patient Assistance Program Flolan Patient Assistance Program ACORDA THERAPEUTICS Zanaflex Uninsured Individual Program ACTAVIS PHARMACEUTICALS Kadian Patient Assistance Program ACTELION PHARMACEUTICALS Tracleer Access Program opt. 1 Ventavis Patient Assistance Program ALAVEN PHARMACEUTICAL Alaven Patient Assistance Program ALCON LABS Alcon Cares ALEXION PHARMACEUTICALS
3 Alexion Complement Foundation ALKERMES, INC. Touchpoints AMERICAN REGENT Venofer Reimbursement Hotline and Patient Assistance Program AMGEN, INC. ENcourage Foundation Safety Net Foundation AMYLIN PHARMACEUTICALS, INC. Amylin Patient Assistance Program - Symlin ARCH FOUNDATION Arch Foundation Patient Assistance Program for Mirena ASCEND THERAPEUTICS Ascend Therapeutics Patient Assistance Program ASTELLAS PHARMA US, INC. Amevive Start Assistance Program Astellas Patient Assistance Program for Organ Transplant
4 Astellas Patient Assistance Program for Vaprisol Astellas Stock Replacement Program Protopic Patient Assistance Program ASTRAZENECA PHARMACEUTICALS AZ & Me Prescription Savings Program for people with Medicare Part D AZ & Me Prescription Savings Program for people without insurance AZ Cancert Support Network - Iressa Access Program ATON PHARMA Aton Pharma Patient Assistance Program AUXILIUM PHARMACEUTICALS, INC. Auxilium Patient Assistance Program AXCAN PHARMA, INC. Assist Program Care First for CF Program Comprehensive Care Program for CF
5 Rx Cost Reduction Program BAXTER HEALTHCARE CORPORATION Alpha-1 SecurityProgram CARES Gammagard Insurance Assistance program GARD (4273) WinRho Reimbursement Support and Patient Assistance Program , opt 3 BAYER HEALTHCARE PHARMACEUTICALS Bayer Patient Assistance Program - Angeliq Bayer Patient Assistance Program - Betapace Bayer Patient Assistance Program - Climara Bayer Patient Assistance Program - Climara Pro Bayer Patient Assistance Program - Menostar Bayer Patient Assistance Program for Precose Betaseron Patient Assistance Program
6 Kogenate Factor Solutions Nexavar REACH Program BEACH PHARMACEUTICALS BIOGEN Idec Access Program BIOMARIN KUVAN Patient Assistance Program Naglazyme Premium/Co-Payment Assistance Program BIOVITRUM Kepivance Patient Assistance Program Kineret Patient Assistance Program BLAIREX LABORATORIES Blairex Laboratories Indigent Program BOEHRINGER INGELHEIM CARES FOUNDATION, INC. Patient Assistance Program
7 Patient Assistance Program for Aptivus & Viramune Patient Assistance Program for Medicare Beneficiaries BRISTOL-MYERS SQUIBB Abilify Patient Assistance Program Access Virology Patient Assistance Program Atripla Patient Assistance Program Bristol-Myers Squibb Patient Assistance Foundation Inc Destination Access ERBITUX / IXEMPRA Patient Assistance Program Destination Access Sprycel Patient Assistance Program Oncology Patient Assistance Program Orencia Patient Assistance Program BTA PHARMACEUTICALS, INC. BTA Patient Assistance Program CELGENE CORPORATION Innohep Patient Assistance Program
8 Patient Support Coordinator CEPHALON, INC. Cephalon Oncology Reimbursement Expertise (CORE) CephalonCares Foundation Patient Assistance Program CETYLITE INDUSTRIES, INC. Cetylite Industries, Inc COLUMBIA LABORATORIES, INC. Medication Coupons option 2 CORNERSTONE BIOPHARMA Spectracef Voucher Program CSL BEHRING CSL Behring Patient Assistance Program CUBIST PHARMACEUTICALS Cubicin Reimbursement Hotline CV THERAPEUTICS CVT Connect Patient Assistance Program
9 DAIICHI SANKYO Daiichi Sankyo Open Care Program DIGESTIVE CARE, INC. Digestive Care, Inc. Assistance Program DIPLOMAT PHARMACY Crohn s Navigator Program ext DURAMED PHARMACEUTICALS, INC. Cenestin Patient Assistance Program Enjuvia Patient Assistance Program ParaGard Patient Assistance Program Seasonique Patient Assistance Program ECR PHARMACEUTICALS ECR Pharmaceuticals Patient Assistance Program EISAI, INC. Aricept Patient Assistance Program Eisai Assistance Program
10 Eisai Assistance Program - Oncology Eisai Neurology Patient Assistance Program Fragmin Reimbursement Assistance Gliadel Wafer Patient Assistance Program ELAN PHARMACEUTICALS Patient Assistance Program for Prialt Tysabri Patient Assistance Program ELI LILLY & COMPANY Forteo Patient Assistance Program Humatrope Reimbursement Center Lilly Cares LillyMedicareAnswers Program PatientOne Xigris Treatment Support Program
11 EMD SERONO Connections for Growth MS Lifelines Serostim Patient Assistance Program ENDO PHARMACEUTICALS, INC. Endo Patient Assistance Program Endo Patient Assistance Program for Opana Endo Patient Assistance Proram for Vantas ENZON Enzon Patient Assistance & Reimbursement Services EUSA PHARMA EUSA Pharma Community Access Patient Program EXPRESS SCRIPTS SPECIALTY DISTRIBUTION SERVICES Rx Outreach FERNDALE LABORATORIES, INC.
12 Ferndale Laboratories Patient Assistance Program , ext 442 FOREST PHARMACEUTICALS, INC Patient Assistance Program FRESENIUS MEDICAL CARE PhosLo Patient Assistance Program Venofer Patient Assistance Program GALDERMA LABORATORIES Patient Assistance Program GENENTECH, INC Access to Care Access to Care - Avastin, Herceptin, Rituxan, Tarceva Access to Care - Lucentis Access to Care - Nutropin (Adult) Access to Care - Nutropin (Pediatric) Access to Care - Pulmozyme
13 Access to Care - Rituxan RA Access to Care - Xolair Avastin Patient Assistance Program GENZYME CORPORATION Charitable Access Program ex Renal Patient Assistance Program , opt 2 Renvela Medicare Part D Assistance Program option 2 Synvisc Reimbursement Hotline GILEAD SCIENCES Gilead Advancing Access Letairis Education and Access Program (LEAP) GLAXOSMITHKLINE Bridges to Access Commitment to Access
14 GSK Access GLENWOOD & WESTERN MEDICAL Glenwood Compassionate Drug Program , ext. 1 GRACEWAY PHARMACEUTICALS Graceway Pharmaceuticals Patient Assistance Program GRIFOLS Grifols Assurance for Patients , option 3 Grifols Patient Assistance Program option 3 GTx, INC. GTx, Inc. Patient Assistance Program INTERMUNE PHARMACEUTICALS Actimmune Patient Assistance Program JAZZ PHARMACEUTICAL,INC. Xyrem Patient Assistance Program JOHNSON & JOHNSON HEALTH CARE SYSTEMS, INC. Janssen Ortho Patient Assistance Foundation KING PHARMACEUTICALS, INC.
15 KingKare Patient Assistance Program LUNDBECK, INC. Patient Assistance Program Xenazine Patient Assistance Program MALLINCKRODT Mallinckrodt Patient Assistance Program MEDA PHARMACEUTICALS Patient Assistance Program MEDIMMUNE, INC. Synagis Patient Assistance Program MEDTRONIC,INC. ITB Therapy Patient Assistance Program option 3 then ex MERCK & COMPANY, INC. ACT for EMEND Act Program - Zolinza Merck Hotline for Cancidas, Invanz & Primaxin
16 Merck Prescription Discount Program SUPPORT Program for Crixivan & Isentress The Merck Patient Assistance Program MERCK/SCHERING-PLOUGH Merck/Schering Plough Patient Assistance Program MILLENNIUM Velcade Reimbursement Assistance Program MISSION PHARMACAL Mission Pharmaceutical Patient Assistance Program MYLAN PHARMACEUTICALS Mylan Clozapine Prescription Access System NICHE PHARMACEUTICALS Niche Pharmaceuticals Patient Assistance Program NITROMED NitroMed Cares Uninsured Patient Program
17 NOVARTIS PHARMACEUTICALS CORPORATION Clozaril Patient Assistance Program EPASS Prescription and Reimbursement Hotline Extavia Patient Assistance Program Ilaris Patient Assistance Program Novartis Oncology Patient Assistance Program Novartis Patient Assistance Foundation Program Novartis Patient Assistance Program for Specialty Medicines Proleukin Reimbursement Service RabAvert Patient Assistance Program Reclast Patient Assistance Program Tobi Patient Assistance Program Visudyne Patient Assistance Program NOVEN THERAPEUTICS, LLC
18 JDS Patient Care Program NOVO NORDISK, INC. Novo Nordisk Diabetes Patient Assistance Program Novo Nordisk Hormone Therapy Patient Assistance Program PFIZER, INC. Connection to Care First Resource - Sutent First Resource Program Pfizer Bridge Program - Genotropin Pfizer Bridge Program - Genotropin (Pedi) Pfizer Bridge Program - Somavert Pfizer Maintain Program Pfizer RSVP Program PRIMUS PHARMACEUTICALS Primus Prescription Discounts
19 PROCTER & GAMBLE PHARMACEUTICALS, INC. Procter & Gamble Pharmaceuticals Patient Assistance Program PURDUE PHARMA Patient Assistance Program QUESTCOR PHARMACEUTICALS,INC. Acthar Gel Patient Assistance RARE DISEASE THERAPEUTICS,INC. Cystadane Patient Assistance Program Orfadin Patient Assistance Program RECKITT BENCKISER Suboxone Patient Assistance Program ROCHE DIAGNOSTIC CORPORATION Roche Diagnostic Corp. Patient Assistance Program ROCHE PHARMACEUTICALS Boniva Patient Assistance Program Roche Oncoline Patient Assistance Program
20 Roche Patient Assistance Program for HCV, HIV, and Transplants ROMARK LABORATORIES Romark Patient Assistance Program for Alinia SALIX PHARMACEUTICALS Salix Pharmaceuticals Patient Assistance Program SANOFI PASTEUR Sanofi Pasteur Patient Assistance Program SANOFI-AVENTIS Eligard Reimbursement Hotline & Patient Assistance Program Hyalgan Hotline and Patient Assistance Program Lovenox Reimbursement Services and Patient Assistance Program Multaq Patient Assistance Program and Reimbursement Hotline PACT+ Patient Assistance Program Rilutek Continuity Program Rilutek Patient Assistance Program or
21 Sanofi-Aventis Patient Assistance Program Sculptra Patient Access Program SCHERING CORPORATION Commitment to Care Program Schering-Plough Cares SCIELE PHARMA, INC. Patient Assistance Program SHIRE PHARMACEUTICALS Carbatrol Patient Assistance Program Fosrenol on Track Program Shire CARES - Lialda Shire CARES - Pentasa Vyvanse Patient Assistance Program SIGMA-TAU PHARMACEUTICALS,INC. Carnitor Drug Assistance Program
22 Matulane Patient Assistance Program SOLVAY PHARMACEUTICALS INC. Solvay Patient Assistance Program SPECTRUM PHAMACEUTICALS, INC. Zevalin Results STIEFEL LABORATORIES StiefelCare Program STRATIVA PHARMACEUTICALS Megace ES Patient Assistance Program TAKEDA PHARMACEUTICALS AMERICA Patient Assistance Program TEVA NEUROSCIENCE,INC. Copaxone Patient Assistance Program TEVA PHARMACEUTICALS Azilect Patient Assistance Program Clozapine Patient Assistance Program
23 Teva Assistance Program Tev-Tropin Patient Assistance Program THE MEDICINES COMPANY Hospital/Patient Assistance Program THREE RIVERS PHARMACEUTICALS Infergen Aspire Patient Assistance Program RibaCare Patient Assistance Program TRIAX PHARMACEUTICALS, LLC Patient Assistance Program UCB PHARMA, INC. UCB Patient Assistance Program UCYCLYD PHARMA,INC. Buphenyl Drug Assistance Program VALEANT PHARMACEUTICALS INTERNATIONAL Cesamet Patient Assistance Program Valeant Patient Assistance - Mysoline
24 Valeant Pharmaceuticals Patient Assistance Program VALIDUS PHARMACEUTICALS Equetro Shire Patient Assistance Program VIROPHARMA Cinryze Solutions Patient Support ViroPharma Patient Assistance Program WATSON PHARMACEUTICAL, INC. Trelstar Reimbursement Assistance Program Watson Iron Reimbursement Assistance Program WELLSPRING PHARMACEUTICAL CORPORATION Wellspring Patient Assistance Program WYETH PHARMACEUTICALS Patient Assistance for Relistor RapAssist - Rapamune Patient Assistance Program Reimbursement Support and Patient Assistance Program
25 Torisel Reimbursent Support and Patient Assistance Program Wyeth Factor Resource Program Wyeth Pharmaceutical Assistance Foundation XUBEX PHARMACEUTICAL Free 30 Day Medication Supply Xubex Pharmaceutical Services
Pharmaceutical Marketing Disclosures
Pharmaceutical Marketing Disclosures July 1, 2007 June 30, 2008 Report of Vermont Attorney General William H. Sorrell April 2009 Prepared by staff of the Vermont Attorney General s Office: Wendy Morgan,
More informationOutcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct
Outcomes of Monitoring Committee Reviews Medicines Australia Code of Conduct 1 Medicines Australia ABN 23 126 990 001 Level 1, 16 Napier Close Deakin ACT 2600 Phone: 02 6122 8500 Fax: 02 6122 8555 Web:
More informationehealthinsight Series: Online Patient Recruitment Strategies
A Datamonitor report ehealthinsight Series: Online Patient Recruitment Strategies Published: May-08 Product Code: Providing you with: Overview of benefits and drawbacks of online Analysis of online patient
More information6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality
6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality March 24-25, 2015 Wyndham Philadelphia Historic District, Philadelphia, PA www.exlevents.com/gcp Sponsors
More informationPPRS 2014 analysis of growth in spend of branded medicines. DH Leading the nation s health and care
PPRS 2014 analysis of growth in spend of branded medicines March 2015 Executive Summary IMS Health data shows growth in spend in 2014 (compared to 2013) of 8.2% on branded medicines. This is higher than
More informationDecision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus)
A Datamonitor report Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus) Published: Oct 07 Product Code: DMTC2133 Providing you with: Identifies which technology vendors
More informationRx-360 An International Pharmaceutical Supply Chain Consortium
Rx-360 An International Pharmaceutical Supply Chain Consortium Overview Rx-360 and the Audit Sharing Program September 2011 Rx-360 Members (Continuously updated list at www.rx-360.org) Manufacturers (24)
More informationCHEM-E4140 Selectivity 12. Pharma Business
CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25
More informationStakeholder Perspectives: Mild Cognitive Impairment and Dementia
A Datamonitor In-Depth Analysis Stakeholder Perspectives: Mild Cognitive Impairment and Dementia Aricept in Race to Pioneer Unexplored Markets Published: Aug-03 Product Code: DMHC1924 Why buy this analysis?
More informationCommercial Insight Osteoarthritis and Rheumatoid Arthritis
A Datamonitor In-Depth Analysis Commercial Insight Osteoarthritis and Rheumatoid Arthritis New Growth In A Mature Market Published: Jul-03 Product Code: DMHC1891 Why buy this analysis? Target current and
More informationM&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends
M&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends Symposium Life Science am Kapitalmarkt Frankfurt, 3. Juni 28 Global biotech industry Strong growth in most areas but Visible product
More informationCO-PAY PROGRAMS FOR HIV and Hepatitis
CO-PAY PROGRAMS FOR HIV and Hepatitis CO-PAY PROGRAMS FOR HIV These programs offer assistance to people with private health insurance for the co-payments they have to make at the pharmacy for their HIV
More informationThe power of creativity www.originbranding.com. Pharmaceutical Branding 2012
The power of creativity www.originbranding.com Pharmaceutical Branding 2012 We are an independent, boutique agency passionately focused on developing pharmaceutical brands. For over 15 years we have delivered
More informationAhighlight of the Pharma 50 ranking
www.pharmexec.com ELECTRONICALLY REPRINTED FROM JUNE 2014 Insight: The Accelerating Growth of Specialty Markets By Waseem Noor and Michael Kleinrock, IMS Photo: Thinkstock Ahighlight of the ranking over
More informationKEEPING CLINICAL TRIALS IN AUSTRALIA
OCCASIONAL PAPER SERIES KEEPING CLINICAL TRIALS IN AUSTRALIA WHY ACTION IS NEEDED NOW OCCASIONAL PAPER SERIES > Medicines Australia is producing Occasional Papers to promote a contest of ideas, thought
More informationINCENTIVE COMPENSATION CONFERENCE
Announcing the 2nd Annual ZS Associates INCENTIVE COMPENSATION CONFERENCE 08 September 23 24, 2008 Philadelphia, PA Incentive compensation greatly affects sales force motivation and morale. When designed
More informationStakeholder Insight: Multiple Sclerosis Disease-modifying Efficacy and Side Effects Guide Treatment Choice
A Datamonitor report Stakeholder Insight: Multiple Sclerosis Disease-modifying Efficacy and Side Effects Guide Treatment Choice Published: Dec-06 Product Code: Providing you with: An overview of epidemiology,
More informationBuilding A Fully Integrated Biotech Company:
BIOPHARMA BIOPHARMA STRATEGIES STRATEGIES Building A Fully Integrated Biotech Company: WHAT IT TAKES The transition from R&D to a fully integrated stage is a make-orbreak scenario for any biotech company.
More informationPharmaceutical industry
8 th March 2016 Pharmaceutical industry 2015 Global ranking strategy decisive The annual company reporting season is always an exciting period. It is an ideal time to update our industry statistics and
More informationStakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm
A Datamonitor report Stakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm Published: Sep-06 Product Code: Providing you with: Disease overview including epidemiology, physician
More informationCommercial Perspectives: Multiple Sclerosis
A Datamonitor Report Commercial Perspectives: Multiple Sclerosis How to Find Opportunities in an Unremitting Market Published: Jun-04 Product Code: Providing you with: In-depth profiles of current market-leading
More informationIt s In The Cards: Pharmaceutical Co-pay and Patient Assistance Programs. Jeff Berry Editor, Positively Aware
It s In The Cards: Pharmaceutical Co-pay and Patient Assistance Programs Jeff Berry Editor, Positively Aware PAPs, Co-Pays, and ADAPs, Oh My! Patient Assistance Programs (PAPs) provide free or low-cost
More informationClinical trial research agreement Agreed schedule 4 or 7 clause amendments
Clinical trial research agreement Agreed schedule 4 or 7 clause amendments Medicines Australia and Medical Technology Association of Australia templates The sponsors in the table have agreed clauses for
More informationMultiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth
Brochure More information from http://www.researchandmarkets.com/reports/2640803/ Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine
More informationGuide. Astellas Pharma US, Inc. XTANDI Access Services SM 2015 NCCN Virtual Reimbursement Resource Room. NCCN.org/reimbursement
Astellas Pharma US, Inc. XTANDI Access Services SM 2015 NCCN Virtual Reimbursement Resource Room Guide The oncology reimbursement landscape continues to present ever-evolving challenges for clinicians
More informationPharma working capital leaves room for improvement
October 2012 Pharma working capital leaves room for improvement 50.7 Billion in Excess Working Capital Ten years ago it was not unusual to be asked why working capital mattered to a pharmaceutical company.
More informationPROGRAM PLAN FOR THE ONTARIO MEDICATIONS RETURN PROGRAM
PROGRAM PLAN FOR THE ONTARIO MEDICATIONS RETURN PROGRAM April 2013 Executive Summary Ontario Regulation 298/12 "Collection of Pharmaceuticals and Sharps - Responsibility of Producers" came into force on
More informationSTAT Bulletin. Drug Therapy Guideline Updates. May 11, 2012 Volume: 18 Issue: 12
STAT Bulletin May 11, 2012 Volume: 18 Issue: 12 To: All primary care physicians and specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat What
More informationPharma working capital performance highly variable
April 2014 Pharma working capital performance highly variable 41 Billion in Excess Working Capital We last completed this survey in 2012. We expected that there would be a broad improvement across the
More informationCampbell Alliance. Press Kit Materials
Campbell Alliance Press Kit Materials Raleigh, N.C. Parsippany, N.J. Woodland Hills, Calif. South San Francisco Chicago New York City TABLE OF CONTENTS Document Page # About Campbell Alliance 3 Company
More informationVAB REPORT: ITS TIME FOR A CHECK UP! UPDATE ON THE HEALTHCARE INDUSTRY
VAB REPORT: ITS TIME FOR A CHECK UP! UPDATE ON THE HEALTHCARE INDUSTRY SUMMARY Healthcare Summary Personal health care expenditures projected to grow 26% in the next 4 years Hospital care sector comprises
More informationAnnual Press Conference 2012. Business Year 2011
Business Year 2011 Highlights of the Business Year 2011 Andreas Barner Chairman of the Board of Managing Directors Corporate Board Division Pharma Research, Development and Medicine Value through Innovation
More informationNCPA 2006 Exhibitors (as of 9/25/06) American Pharmacists Association www.aphanet.org Booth 907. /alert Marketing www.alertmarketing.
NCPA 2006 Exhibitors (as of 9/25/06) /alert Marketing www.alertmarketing.com Booth 530 21st Century Healthcare www.21stcenturyvitamins.com Booth 147 A & D Medical Lifesource www.lifesourceonline.com Booth
More informationKey Findings. Use this report to... The Autoimmune Market Outlook to 2013
Key Findings The global autoimmune market generated sales of $31.9bn in, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013.
More informationGlobal Non-Small Cell Lung Cancer Therapeutics Market 2015-2019
Brochure More information from http://www.researchandmarkets.com/reports/3453273/ Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Description: About non-small cell lung cancer therapeutics
More informationPipeline Insight: Schizophrenia Asenapine; A future market leader?
A Datamonitor report Pipeline Insight: Schizophrenia Asenapine; A future market leader? Published: Jul-06 Product Code: DMHC2186 Providing you with: Detailed pipeline analysis for key products in development
More informationStakeholder Insight: Insulin Use in Type 2 Diabetes
A Datamonitor Report Stakeholder Insight: Insulin Use in Type 2 Diabetes From Last Resort to Early Intervention Published: May-04 Product Code: DMHC1989 Providing you with: Analysis of Datamonitor s Diabetes
More informationPertuzumab in Trastuzumab- Treated, Advanced HER2-Positive Breast Cancer
Pertuzumab in Trastuzumab- Treated, Advanced HER2-Positive Breast Cancer For more visit ResearchToPractice.com/5MJC CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians and basic scientists
More information全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report
/wepdwukltuyot 全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report 联 系 购 买 电 话 :010-82863480 公 司 名 称 : 佐 思 信 息 公 司 地 址 : 北 京 市 海 淀 区 苏 州 街 18 号 院 长 远 天
More informationThe Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011
Brochure More information from http://www.researchandmarkets.com/reports/344881/ The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts
More informationInsurance and Reimbursement Resources for MDS Patients
Insurance and Reimbursement Resources for MDS Patients A Guide to Assistance Programs in the United States Third Edition the myelodysplastic syndromes foundation, inc. Published by The Myelodysplastic
More informationOFFICE OF ATTORNEY GENERAL LAWRENCE G. WASDEN AVERAGE WHOLESALE PRICE LITIGATION REPORT AUGUST 2013
Introduction OFFICE OF ATTORNEY GENERAL LAWRENCE G. WASDEN AVERAGE WHOLESALE PRICE LITIGATION REPORT AUGUST 2013 In 2007, Attorney General Wasden filed lawsuits against 33 pharmaceutical companies for
More informationNew Treatments. For Bipolar Disorder. Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine
New Treatments For Bipolar Disorder Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine Abbott Laboratories AstraZeneca Bristol-Myers Squibb Corcept
More informationREVISING SPECIALTY TIERS
WHITE PAPER REVISING SPECIALTY TIERS PROTECTING MEDICARE PART D BENEFICIARIES FROM BURDENSOME COST SHIFTING Gary G., Michigan Gary thought he had his financial assistance grant set up to cover his out-of-pocket
More informationSpecialty Drug Program RX Benefit Member Guide
Specialty Drug Program RX Benefit Member Guide bcbsm.com Enrollment Form for Walgreens Specialty Pharmacy, LLC. How to place your initial order with Walgreens Specialty Pharmacy: 1) Print and complete
More informationIn the largest and perhaps the most ambitious collaborative
FEATURES THE BIRTH OF TRANSCELERATE BIOPHARMA, INC. Revolution in Clinical Research Partnerships by Dalvir Gill and Garry Neil In the largest and perhaps the most ambitious collaborative effort ever initiated
More informationThe 2015 Avoca Report. Clinical Development Innovation. Sponsor and Provider Views on Innovation in Outsourced Clinical Development
The 2015 Avoca Report Clinical Development Innovation Sponsor and Provider Views on Innovation in Outsourced Clinical Development Contents Section Slides Research Overview 3-5 Respondent Demographics 6-9
More informationSpecialty Pharmacy. Business Plan. July 8, 2013. 2013 RUSH University Medical Center
Specialty Pharmacy Business Plan July 8, 2013 Specialty Pharmaceuticals What are they? Biotech/gene-based therapy Require special handling Newer products oral or self- administered One third have REMS
More informationPATIENT ASSISTANCE PROGRAMS
PATIENT ASSISTANCE PROGRAMS Definitions SAP Class I Class II BC Cancer Agency Health Canada Special Access Program Reimbursed for active cancer or approved treatment or approved indication only Reimbursed
More informationSaving Money on Prescription Drugs
Reference Guide to Saving Money on Prescriptions Revised: July 11, 2006 Prescription medications can be a heavy financial burden for individuals and families. Many people feel limited to receiving assistance
More informationEU Clinical Trials Register
EU Clinical Trials Register Sponsor Contact Information Abbott Laboratories Ltd Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire SL6 4XE UK Telephone number +44 1628 644475 euclinicaltrials@abbott.com
More informationRx-360Upstream Supply Chain Security A Supplier Collaborative Approach to Mitigate Risk and Enhance Transparency
Rx-360Upstream Supply Chain Security A Supplier Collaborative Approach to Mitigate Risk and Enhance Transparency www.rx-360.org www.rx-360.org Presenter: Rob Welsh, VWR International, LLC VP Category Management
More informationPatient Assistance Programs
Patient Assistance Programs *Free Medication Programs *Discounted Medication *Discount Drug Cards *Reimbursement Programs *Glaucoma Medication Programs Since all drugs can not be listed here that patients
More informationThe United States False Claims Act Qui Tam Whistleblower Law
The United States False Claims Act Qui Tam Whistleblower Law Getnick & Getnick LLP Counsellors At Law Rockefeller Center, 620 Fifth Avenue New York, NY 10020 Phone: (212) 376-5666 Fax: (212) 292 3942 www.getnicklaw.com
More informationMetastatic Breast Cancer - Pipeline Review, Q1 2011
Brochure More information from http://www.researchandmarkets.com/reports/1524592/ Metastatic Breast Cancer - Pipeline Review, Q1 2011 Description: Metastatic Breast Cancer - Pipeline Review, Q1 2011 Summary
More informationProduct Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants
Brochure More information from http://www.researchandmarkets.com/reports/1841621/ Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants Description: Introduction Beginning with
More informationComplying with the FCPA - An Exploration of Ethical Issues Raised by Recent Cases: Lessons Learned from Recent Enforcement Actions
Complying with the FCPA - An Exploration of Ethical Issues Raised by Recent Cases: Lessons Learned from Recent Enforcement Actions Philip S. Brewster Brewster Law Firm LLC July 29, 2014 Schering Charitable
More informationStakeholder Insight: Non-Small Cell Lung Cancer The Need for Greater Product Differentiation in an Increasingly Crowded Market
A Datamonitor report Stakeholder Insight: Non-Small Cell Lung Cancer The Need for Greater Product Differentiation in an Increasingly Crowded Market Published: Oct-06 Product Code: DMHC2223 Providing you
More information(SAMPLE COPY, NOT FOR RESALE)
TriMark Publications June 2009 Volume: TMRTMA09-0601 THERAPEUTIC MONOCLONAL ANTIBODIES MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF
More informationPatient Financial Assistance Application
This application is used to evaluate your eligibility for the University of Texas MD Anderson Cancer Center s Patient Financial Assistance Program. To ensure prompt review of your application, please complete
More informationDecember 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES
December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES by Dennis van Rooij with Tim van Tongeren EXECUTIVE SUMMARY More than half of pharma marketers don t or can t leverage
More informationAvoca s Quality Metrics Consulting Service Offering
Avoca s Quality Metrics Consulting Service Offering Avoca s Quality Metrics Consulting The Challenge Biopharmaceutical companies and CROs struggle in defining how best to utilize quality metrics to optimize
More informationOracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries
Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries April 16, 2010 Oracle is currently reviewing the existing Phase Forward product roadmap and will be
More informationN/A N/A N/A. Supporting statement of diagnosis from the N/A. physician and documented trial of 1 generic. formulary alternative
Actimmune Amlodipine Androderm Anticonvulsant Antidepressants Antineoplastics Antipsychotics Arcalyst Butalbital Colony Stimulating Factors ESRD Therapy Actimmune Norvasc Androderm Banzel Keppra Mysoline
More informationdrugs in development CuraScript Specialty Pharmacy Management Guide & Trend Report
CuraScript Specialty Pharmacy Management Guide & Trend Report Drugs in Development There are currently more than 324 drugs in development for nearly 150 disease states. These potential new medications
More informationPatient Assistance Programs
Patient Assistance Programs *Free Medication Programs *Discounted Medication *Discount Drug Cards *Reimbursement Programs *Glaucoma Medication Programs Since all drugs can not be listed here that patients
More informationFamily Practitioners, General Practitioners, Internists, Physician Assistants, Nurse Practitioners, and Nurses
36 th Annual Family Practice Review Online Planned and produced in accordance with the ACCME essentials. RELEASE DATE: February 25, 2013 EXPIRATION DATE: February 25, 2015 Physicians $750 Non-Physicians
More informationStakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity
Brochure More information from http://www.researchandmarkets.com/reports/1383065/ Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity Description: Introduction Disease-modifying
More informationDigital Leaders Deal With a Range of Organizational Challenges
May 22, 2014 OVERCOMING OBSTACLES TO DIGITAL TRANSFORMATION SUCCESS IN THE PHARMACEUTICAL INDUSTRY Digital Leaders Deal With a Range of Organizational Challenges by Tim van Tongeren with Dennis van Rooij
More informationGlobal Peptide Therapeutics Market 2014-2018
Brochure More information from http://www.researchandmarkets.com/reports/3022209/ Global Peptide Therapeutics Market 2014-2018 Description: About Peptide Therapeutics Peptides are amino acids sequences
More informationTop ICT spenders in the US Pharmaceutical Industry - Estimated ICT budget breakdowns in 2013
Brochure More information from http://www.researchandmarkets.com/reports/2599260/ Top ICT spenders in the US Pharmaceutical Industry - Estimated ICT budget breakdowns in 2013 Description: Synopsis This
More informatione-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015
e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015 PHARMAPACK 2015 1 Mobile health x2 30 months 100 000 mapps Source: research2guidance, mhealth App Market Report 2013-2017
More informationHBM Pharma/Biotech M&A Report 2013
January HBM Pharma/Biotech M&A Report Trade Sales of European and North American Biopharma Companies - Key Findings Total (upfront) transaction value reached $. billion (vs. $.6 billion in ), not including
More informationAgenda. Medicare Overview Medicare Part B Drug Coverage Medicare Part D: How to Find and Compare Medicare Part D Plans Summary Provider Contacts
2 Medicare Part D Agenda Medicare Overview Medicare Part B Drug Coverage Medicare Part D: Background Benefits of Medicare Part D Enrollment Coverage Specialty Medications Part D Costs How to Find and Compare
More informationSmall-Cell Lung Cancer Global Clinical Trials Review, H2, 2015
Brochure More information from http://www.researchandmarkets.com/reports/3398017/ Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 Description: Small-Cell Lung Cancer Global Clinical Trials
More informationWHITE PAPER PHARMERGING MARKETS. Pharmerging markets. Picking a pathway to success
WHITE PAPER PHARMERGING MARKETS Pharmerging markets Picking a pathway to success PHARMERGING MARKETS 1 With slow growth for pharmaceutical sales in developed markets, multinational companies (MNCs) have
More informationGrowth in revenue from MS drugs has been driven largely by price increases over the last several years.
March 4, 2013 Ben Weintraub, PhD Are Injectable MS Drugs Finished? Market Ready for Tecfidera Companies: Biogen (BIIB) Sanofi (SNY) Teva (TEVA) Novartis (NVS) Merck Serono Bayer Schering Products: Tecfidera
More informationManufacturer of drug substance
Original s and Biosimilars (marketing authorizations in the EU) Date: January 2016 1) Somatropin s ORIGINAL PRODUCTS: Authorization Genentech Genotropin Somatropin Pharmacia/ Pfizer E. coli Humatrope Somatropin
More informationSpecialty Pharmacy: Understanding the Market and Solution. Your Goals. Presented by Chris Brown November 2009
Specialty Pharmacy: Understanding the Market and Solution Presented by Chris Brown November 2009 Your Goals What What is a Specialty is a specialty Medication? medication? Specialty drugs are injectable,
More informationPharmaceutical sales in Canada have a 2.5 percent share of the global market, making th
Industry Canada (/eic/site/icgc.nsf/eng/home) Home Industries and Business Canadian Life Science Industries Biopharmaceuticals and pharmaceuticals Pharmaceutical industry profile Life Science Industries
More informationPlan representatives and advisors will be available to answer your individual questions..
Medicare Awareness Day for 2008 Tuesday, October 30, 2007 Frank Van Nostrand from Social Security and Julie Schoen from HICAP will help us Navigate through the new plans. Plan representatives and advisors
More informationMultiple Sclerosis Treatments: World Market Outlook to 2011
Brochure More information from http://www.researchandmarkets.com/reports/2860814/ Multiple Sclerosis Treatments: World Market Outlook to 2011 Description: Multiple sclerosis (MS) is a chronic demyelinating
More informationPHARMACEUTICAL INDUSTRY PROFILE
PHARMACEUTICAL INDUSTRY PROFILE I. INDUSTRY BACKGROUND A. Industry Definition The U.S. pharmaceutical industry is defined by the Census Bureau as companies engaged in researching, developing, manufacturing,
More informationWORLD PREVIEW 2014, OUTLOOK TO 2020
WORLD PREVIEW 2014, OUTLOOK TO 2020 June 2014 Welcome to the EvaluatePharma World Preview 2014, Outlook to 2020 The seventh edition of EvaluatePharma s World Preview brings together many of our analyses
More information2014 & 13 th Annual China Pharmaceutical, Life Science & Healthcare Industry Summit
2014 & 13 th Annual China Pharmaceutical, Life Science & Healthcare Industry Summit Addressing the most critical issues facing China s pharma & life science sector 10 th & 11 th April, 2014 Shanghai China
More informationPARTIAL DELEGATE LIST (as of Jan. 15, 2013) Electronic Data in Clinical Trials /Integration and Leveraging Clinical Trial Operations Data Conferences
PARTIAL DELEGATE LIST (as of Jan. 15, 2013) Electronic Data in Clinical Trials /Integration and Leveraging Clinical Trial Operations Data Conferences February 5-7, 2013 - Hyatt Regency Miami Miami, FL
More informationLife Sciences Outlook. New Jersey 2015
Life Sciences Outlook New Jersey 2015 New Jersey M&A activity in New Jersey has led to the consolidation of surplus real estate holdings and diminished head counts. However, midsized companies are helping
More informationCase 1:15-cv-01120-UNA Document 1 Filed 12/03/15 Page 1 of 49 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:15-cv-01120-UNA Document 1 Filed 12/03/15 Page 1 of 49 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE UNIMED PHARMACEUTICALS, LLC, BESINS HEALTHCARE INC., and BESINS
More informationCOMMUNICATIONS. CLIENT LIST BY INDUSTRY (*) Denotes companies whose CEOs Dan Broden has trained
BRODEN COMMUNICATIONS CLIENT LIST BY INDUSTRY (*) Denotes companies whose CEOs Dan Broden has trained AIRLINE Delta Airlines Orbitz* AUTOMOTIVE Allison Transmission* General Motors Hyundai* CONSUMER GOODS
More informationMain Conference Agenda
Sponsored by: (Co-located with Bioequivalence: Intersection between Science & Regulatory Conference) Main Conference Agenda Day One Wednesday, November 5 th, 2014 7:30 Registration Opens & Continental
More informationCONNECTICARE, INC. & AFFILIATES
CONNECTICARE, INC. & AFFILIATES INSERT PAGE FOR PRE-CERTIFICATION AND PRE- AUTHORIZATION LISTS UPDATE Applies to all ConnectiCare health plans, except the ConnectiCare Network USA-PPO Plan and as otherwise
More informationClinical Trial Logistics
BOOK BY 31ST MARCH TO SAVE 100 SMi presents the 8th conference and exhibition series... Clinical Trial Logistics 21ST - 22ND MAY 2014 MARRIOTT REGENTS PARK LONDON, UK EUROPE'S LEADING CLINICAL TRIAL LOGISTICS
More informationPost-PharmD Industry Fellowship Opportunities and Proposed Guidelines for Uniformity
SPECIAL ARTICLE American Journal of Pharmaceutical Education 2009; 73 () Article 20. Post-PharmD Industry Fellowship Opportunities and Proposed Guidelines for Uniformity Paul A. Larochelle, PharmD, a *
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE August 20, 2015 SUBJECT EFFECTIVE DATE September 28, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER 99-15-08 BY Specialty Pharmacy Drug Program Pharmacy Services Leesa M. Allen, Deputy Secretary Office
More informationNovel Opportunities for Engagement Utilizing in House Pharmacy Services
Novel Opportunities for Engagement Utilizing in House Pharmacy Services Ray Bailey, BSPharm RPh Director of Pharmacy, FCS Rx to Go Pharmacy rbailey@flcancer.com Angel Aslo, Pharm.D. Director of Pharmacy,
More informationEvaluatePharma World Preview 2015, Outlook to 2020
EvaluatePharma World Preview 2015, Outlook to 2020 8th Edition June 2015 Welcome to the EvaluatePharma World Preview 2015, Outlook to 2020 The eighth edition of EvaluatePharma s World Preview brings together
More informationNorthwest Georgia Oncology Centers, P.C.
Northwest Georgia Oncology Centers, P.C. High Deductibles and Out of Pocket HSA/HRA Plans (No up front collection) Medicare Advantage Plans Healthcare Exchange Plans Medicare only Cobra plans/high premiums
More informationPUBLIC SETTLEMENTS & INVESTIGATIONS
RECENT SETTLEMENTS AND INVESTIGATIONS RELATED TO MARKETING, PRICING AND ASSOCIATED ACTIVITIES PUBLIC SETTLEMENTS & INVESTIGATIONS PREPARED BY EPSTEIN BECKER & GREEN, P.C. This chart summarizes publicly
More informationThe Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals
The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals Michelle Gittelman Department of Business and Management Rutgers Business School Newark-New Brunswick, New Jersey The pharmaceutical
More informationGlobal Multiple Sclerosis Market: Trends and Opportunities (2013-18)
Global Multiple Sclerosis Market: Trends and Opportunities (2013-18) Scope of the Report The report titled Global Multiple Sclerosis Market: Trends & Opportunities (2013-18) provides an insight into the
More information